#Canada #Toronto #CDI Labs #PhIP-Seq #Hormones

CDI Labs Canada Launches Hormone-focused PhIP-Seq Library

CDI Labs Canada Inc. has recently unveiled its new Peptide Hormone PhIP-Seq Library, a significant advancement in the analysis of serum autoantibodies. This innovative product combines phage display immunoprecipitation sequencing (PhIP-Seq) with state-of-the-art proteomic technology, enabling researchers to conduct highly multiplexed analyses of autoantibody responses, specifically targeting peptide hormones and hormone fragments.

The Importance of Autoantibodies in Hormone Studies

The characterization of autoantibodies that react to peptide hormones is a rapidly evolving field of research in medicine. These antibodies have been implicated in various disorders related to appetite regulation such as anorexia nervosa, bulimia, and obesity, as well as in thyroid conditions like Hashimoto's thyroiditis and Graves' disease. The implications of this research are immense, as understanding these autoantibodies can lead to better diagnostic and therapeutic strategies.

Dr. Barney Saunders, CEO of CDI Labs, explains, "Autoantibodies reactive to peptide hormones have been identified in both health and disease; their study offers great potential to further our understanding of human disease. However, these interactions remain poorly characterized, partly due to limitations in traditional autoantibody profiling methods. Our new Peptide Hormone Library addresses this bottleneck and offers a cost-effective and high-throughput tool for researchers to probe these vital autoantibody responses."

A Deeper Look at PhIP-Seq Technology

PhIP-Seq is a powerful methodology that supports large-scale and detailed antibody analysis. By integrating next-generation proteomics with high-throughput DNA sequencing, it facilitates an efficient analysis of a multitude of interactions simultaneously. This technology is particularly beneficial for researchers looking to understand the intricate relationships between hormones, antibody responses, and various disease states.

CDI Labs Canada already offers an existing suite of PhIP-Seq services that enrich this new library. These include:

• - HuScan® and MouseScan™: These services allow for antibody analysis against a complete human or mouse proteome in a single-well assay with quantitative sequencing results.
• - VirScan®: This service enables comprehensive epitope-level antibody profiling across various vertebrate viral proteomes.

All of these advanced methodologies are available through CDI Labs Canada, based in Toronto, Ontario, highlighting its status as a leader in proteome analysis and antibody profiling.

CDI Labs Canada: Innovating Protein Analysis

CDI Labs has established itself as a specialized contract research organization (CRO) that offers cutting-edge lab services in proteomics. Empowered by advanced synthetic biology platforms, it boasts the world’s largest collection of proteomes. CDI Labs has assembled a team with deep expertise in proteomics, enabling it to provide unique services designed to elucidate molecular interactions across entire proteomes. Their solutions span various stages including basic research, discovery, validation, and clinical deployment.

Moreover, CDI Labs is committed to helping its customers with autoantibody biomarker discovery, viral exposure profiling, immunogenicity assessments of various therapies, and targeted identification for monoclonals and biologics.

To learn more about the full range of services offered by CDI Labs, visit their website at cdilabs.com.

Conclusion

The launch of the Peptide Hormone PhIP-Seq Library by CDI Labs Canada marks a pivotal moment for researchers focusing on hormone-related studies. As the scientific community aims to unravel the complexity of hormone-targeting autoantibodies, this new library is poised to become an invaluable tool, offering unprecedented insights into human health and disease. With CDI Labs at the forefront of this innovation, the future of hormone research looks more promising than ever.